Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20781186 | 1.00 | LMNA (0.44) | LMNAMAPK1HTTNCF1HRH4 | |
| SCHEMBL20090727 | 0.80 | NCF1 (0.37) | NCF1SMN1; SMN2ALDH1A1 | |
| SCHEMBL14282247 | 0.77 | LMNA (0.40) | LMNAMAPK1HTT | |
| SCHEMBL284533 | 0.77 | — | — | |
| SCHEMBL408223 | 0.77 | — | — | |
| SCHEMBL284532 | 0.77 | — | — | |
| SCHEMBL24378857 | 0.77 | NCF1 (0.39) | LMNAMAPK1HTTNCF1SMN1; SMN2 | |
| SCHEMBL15451922 | 0.77 | SMN1; SMN2 (0.60) | LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL2899053 | 0.77 | LMNA (0.41) | LMNAMAPK1HTTHRH3ALDH1A1 | |
| SCHEMBL13135836 | 0.77 | LMNA (0.41) | LMNAMAPK1HTTHRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117597342-A | Pyrrolidine derivative, pharmaceutical composition and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023237103-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2023-12-14 | — | — | WO | disclosed |
| US-9751873-B2 | Aryl sultam derivatives as RORc modulators | GENENTECH, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2872504-B1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | disclosed |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2015104356-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-07-16 | — | — | WO | disclosed |
| WO-2014009447-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168141-A1 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORB, RORA | LMNA 3495/4885MAPK1 3546/4885HTT 2852/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | LMNA 4176/4885MAPK1 362/4885HTT 1029/4885 |
| US-20160311817-A1 | HETEROARYL SULTAM DERIVATIVES AS RORc MODULATORS | RORC, RORA, RORB | LMNA 3502/4885MAPK1 3109/4885HTT 2811/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | LMNA 4176/4885MAPK1 362/4885HTT 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.